Dry eye, Sjögren and systemic view

An integrative perspective that complements, and does not replace, evidence-based definitions and treatments.

Le informazioni riportate hanno finalità esclusivamente informative e non sostituiscono visita oculistica, linee guida ufficiali o il parere dei medici curanti. Ogni scelta diagnostica o terapeutica va concordata caso per caso con i propri specialisti.

Dry eye: more than a "dry" surface

Dry eye disease is defined by clinical criteria and international guidelines. From a systemic-medicine standpoint, these criteria remain the main reference; in addition, clinicians may consider whether ocular surface disease fits into a broader picture involving mucosae, metabolism, nervous system, hormones and lifestyle. This page describes possible correlations only, without proposing single-cause explanations or alternative therapies.

Possible systemic correlations

Additional viewpoints that sit alongside, not instead of, core ophthalmic care.

1. Gut symptoms and autoimmune disease

Some patients with dry eye and autoimmune conditions report gastrointestinal symptoms or altered gut balance. This does not mean that the gut "causes" dry eye, but that, in complex cases, it may be reasonable to coordinate assessment with rheumatologists, internists or gastroenterologists.

2. Stress, sleep and ocular pain

A subset of patients experience intense burning even when clinical signs are moderate. A neuropathic pain component has been hypothesised, in which chronic stress, anxiety and sleep disturbance may contribute to heightened nerve sensitivity. In such situations, ophthalmic treatment can be complemented by pain- and stress-focused care, when deemed appropriate by the specialist.

3. Meibomian glands and ocular microbiota

Meibomian gland function and lid margin health are influenced by local factors (hormones, lid hygiene, environment) and by the microbial flora at the lid margin. Some patients show denser or foamy secretions and higher bacterial load. Standard therapy (hygiene, anti-inflammatory care, targeted procedures) remains central; the idea of an "ocular ecosystem" simply underlines that several elements contribute to tear-film stability.

4. Metabolic, hormonal and low-grade inflammation

Conditions such as metabolic syndrome, diabetes, thyroid dysfunction and hormonal changes (for example peri- and post-menopause) are often associated with dry eye symptoms. Not all patients share these features, but when they are present, coordination between ophthalmologist, primary-care physician and other specialists is advisable so that ocular and systemic management stay aligned.

5. Environment, screens and lifestyle

Air conditioning, low humidity, smoke exposure, intensive screen use and reduced blinking can worsen dry eye symptoms. A systemic view does not replace drops or regulated therapies, but emphasises the value of practical measures (visual breaks, humidification, protection outdoors) and lifestyle choices that reduce overall irritative burden.

Scorri i fattori

Diagnosis: combining ocular and general assessment

Dry eye diagnosis relies on eye examination, medical history and specific tests on tear film, inflammation and gland function. When general symptoms, known autoimmune diseases, metabolic disorders or hormonal issues are present, involving other specialists can be helpful. The aim is to integrate standard ophthalmic protocols with a broader view of the person, not to replace them.

Advanced therapies in current practice

Cyclosporine and topical immunomodulators

In moderate-to-severe dry eye, especially with marked inflammation, topical cyclosporine or other immunomodulators may be prescribed by the ophthalmologist to modulate chronic surface inflammation. These are regulated therapies, to be prescribed and monitored according to specialist indication. A systemic approach sees them as core treatments that can be complemented by work on comorbidities and lifestyle, never replaced.

Cyclosporine details →

Autologous serum and advanced tear substitutes

In selected, severe cases — markedly damaged ocular surfaces or dry eye refractory to conventional therapies — eye drops prepared from the patient's own blood (autologous serum or derivatives) may be considered. These preparations provide tear-like components and growth factors. They are specialist therapies, to be evaluated only after complete assessment and within centres following dedicated protocols.

Autoserum details →

Scorri terapie

Frequently asked questions on dry eye and systemic view

No. Diagnosis and treatment of dry eye must follow scientific-society recommendations and regulatory indications. The systemic view is a way to add information (comorbidities, lifestyle, involvement of other organs) to the evidence-based ophthalmic work you already receive.

No. Many people have predominantly "local" dry eye, driven by glands, tear film and environment. Systemic considerations become more relevant when there are general symptoms, known autoimmune or metabolic diseases, or pain that cannot be explained by ocular findings alone.

No. The content on this page is for general education only. Diagnosis, tests, therapies and decisions about systemic investigations must always be made with your ophthalmologist and, when needed, other physicians.

Dry eye, Sjögren and systemic view

Dry eye: more than a "dry" surface

Possible systemic correlations

Diagnosis: combining ocular and general assessment

Advanced therapies in current practice

Frequently asked questions on dry eye and systemic view

Does the systemic approach replace official dry eye guidelines?

If I have dry eye, do I always have a systemic disease?

Can this information replace my eye doctor's advice?

Network and further reading